Debt Capital Markets: A Panel of Experts Looks Ahead [Video]
Blog post
The Case for Adopting Fintech Innovations in Hong Kong
Blog post
Many banks in Hong Kong’s financial services industry have reaped first-mover advantages such as improved cost efficiency and profitability. We examine the building blocks of their success and explore potential roadblocks and challenges other banks are facing.
Private Credit and Fixed Income Strategies: Six Takeaways From the SS&C Intralinks Alternative Investments Virtual Summit [Video]
Blog post
As fixed income continues to underperform, investors and managers have found new ways to create value in these markets. How have these strategies evolved in the past five years? What will happen in 2021 and beyond?
APRA’S New CPS 234 Prudential Standard: What You Need To Know Now
Blog post
Ray Giblett from law firm Norton Rose Fulbright and Alex Turner from SS&C Intralinks demystify recent regulations concerning the security of information assets.
Legacy LIBOR Extension: It Ain't Over ’Til It's Over
Blog post
Here’s a reminder about what you need to know about the upcoming transition.
On-Demand Webinar
It's Still the Final Countdown for LIBOR
Blog post
On November 30, financial regulators announced revised timelines for the expiration of LIBOR for legacy contracts. Meanwhile, December 2021 remains the deadline for banks to stop issuing new LIBOR-based contracts. Given these developments, what should firms saddled with legacy, tough legacy and non-legacy contracts do?
SS&C Intralinks Surveyed DCM Investors Worldwide About Plans for 2021. Here’s What They Said.
Blog post
As markets sway and uncertainty continues to reign, we surveyed a diverse group of investors active in the debt capital markets (DCM) from across the globe.
COVID-19, Securitization and Deal Marketing: 4 Takeaways from 2020
Blog post
Volatility and uncertainty have reigned in 2020, and segments of the debt capital markets witnessed varying fates throughout the year. Amid a lingering pandemic, some promising geopolitical and medical developments, and continued investor demand for opportunity and yield, how can issuers and banking teams keep moving securitization deals forward?
White Paper